RSS-Feed abonnieren
DOI: 10.1055/s-2000-7358
Östrogenersatztherapie und Koronare Herzerkrankung
Publikationsverlauf
Publikationsdatum:
31. Dezember 2000 (online)

Über die Indikation zur Hormonersatztherapie in der Menopause bei der koronaren Herzerkrankung, deren positive Wirkung und auch deren potenzielle Nebenwirkungen herrscht häufig eine große Unsicherheit. Das kann dazu führen, dass Patientinnen einerseits günstige Effekte durch zu enge Indikationsstellung vorenthalten werden. Andererseits ist bei zu weiter Indikationsstellung oder Verordnung eines »falschen Hormonpräparates« mit Nebenwirkungen zu rechnen, die in keinem adäquaten Verhältnis zu den günstigen Wirkungen stehen. In dieser Arbeit soll eine Übersicht über die Wirksamkeit und Sicherheit der Hormonersatztherapie bei koronarer Herzkrankheit anhand des derzeitigen Standes der Literatur gegeben werden.
Literatur
- 1
Andersson B, Mattsson L, Hahn L, Märin P, Lapidus L, Hohn G, Bengtsson B, Björntorp B.
Estrogen
replacement therapy decreases hyperandrogenecity and improves glucose
homeostasis and plasma lipids in postmenopausal women with noninsulin dependent
diabetes mellitus.
J Clin Endocrinol
Metabol.
1997;
82
638-643
MissingFormLabel
- 2
Bounameaux H, de
Moerloose P, Campanne A.
Contraception
orale et substitution hormonale de la menopause.
Schweiz Med
Wschr.
1996;
126
1756-1763
MissingFormLabel
- 3
Collaborative study of cardiovascular disease and
steroid hormone
contraception.
Contraception.
1998;
57
315-324
MissingFormLabel
- 4
Col N F, Eckmann M H, Karas R H, Paucker S G, Goldberg R J, Ross E M, Orr R K, Wong J B.
Patient-specific
decisions about hormone replacement therapy in postmenopausal
womens.
J Am Med
Ass.
1997;
277
1140-1147
MissingFormLabel
- 5
Colditz G A, Willett W C, Stampfer M J. et
al .
Menopause and the risk of coronary heart disease in
women.
N Engl J
Med.
1987;
316
1105-1110
MissingFormLabel
- 6
Colditz G A, Hankinson S E, Hunter D J.
et al .
The use of estrogens and progestins and the risk of breast
cancer in postmenopausal women.
N Engl J
Med.
1995;
332
1589-1593
MissingFormLabel
- 7
Daly E, Vessey M P, Hawkins M M. et
al .
Risk of venous thromboembolism in users of hormone replacement
therapy.
Lancet.
1996;
348
977-980
MissingFormLabel
- 8
Dunn N, Thorogood M, Faragher B. et
al .
Oral contraceptives and myocardial infarction: results of the
MICA case-control study.
Brit Med
J.
1999;
318
1579-1584
MissingFormLabel
- 9
Ettinger P, Friedman G D, Bush R, Quesenburg
jr C P.
Reduced mortality associated with
long-term postmenopausal estrogen therapy.
Obstet
Gynecol.
1996;
87
1-7
MissingFormLabel
- 10
Folsorn A R, Mink P J, Selleres T A, Hong C P, Zheng W, Potter J D.
Hormonal
replacement therapy and morbidity and mortality in a prospective study of
postmenopausal women.
Am J Public
Health.
1995;
85
1128-1132
MissingFormLabel
- 11
Gorsky R D, Koplan J P. et
al .
Relative risks and benefits of longterm estrogen replacement
therapy.
Obstet
Gynecol.
1994;
83
161-166
MissingFormLabel
- 12
Grady D, Rubin S M, Petitti D, Fox C S, Black D, Ettinger B, Ernster V, Cummings S R.
Hormone
replacement therapy to prevent disease and prolong life in postmenopausal
women.
Ann Int
Med.
1992;
117
1038-1041
MissingFormLabel
- 13
Grodstein F, Stampfer M J, Colditz G A.
Postmenopausal
hormone therapy and mortality.
N Engl J
Med.
1997;
336
1769-1775
MissingFormLabel
- 14
Grodstein F, Stampfer M J, Manson J E, Colditz G A, Willet W C, Rosner B, Speizer F, Hennekens C H.
Postmenopausal
estrogen and progestin use and the risk of cardiovascular disaese.
N
Engl J
Med.
1996;
335
453-461
MissingFormLabel
- 15
Grodstein F, Stampfer M J, Goldhaber S Z, Manson J E, Coldis G A, Speizer F E, Willett W C, Hennekens C H.
Prospective
study of exogenous hormones and risk of pulmonary embolism in
women.
Lancet.
1996;
248
1183-1186
MissingFormLabel
- 16
Hennekens C H.
Hormone
replacement therapy: Current perspectives and future directions.
Eur
Heart
J.
1997;
19
1362-1363
MissingFormLabel
- 17
Hertfelder H J, Hanfland P.
Blutgerinnungsveränderungen
unter Ovulationshemmung, in der Schwangerschaft und in der
Postmenopause.
Herz/Kreislauf.
1999;
31
109-112
MissingFormLabel
- 18
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Vittinghoff E. for
the Heart and Estrogen/Progestin Replacement study (HERS) research
group .
Rado○ized ▾rial of
e▴▾roge plu▴ proge▴▾i for
▴ecodar▮ preve▾io of
coroar▮ hear▾ di▴ea▴e i
po▴▾○eopau▴al wo○e.
J Am Med
Ass.
1998;
280
605-623
MissingFormLabel
- 19
Jick H, Derby L E, Myers M W, Vasilaikis C, Newton K M.
Risk
of hosptital admission for idiopathic venous thromboembolism among users of
postmenopausal
estrogens.
Lancet.
1996;
348
981-983
MissingFormLabel
- 20
Jordan V C.
Designer-Östrogene:
Neuartige Prävention gegen Brustkrebs und Osteoporose.
Spektrum
der
Wissenschaft.
1999;
✗
66-73
MissingFormLabel
- 21
Koh K K, Mincemoyer R, Bui B N, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon R O.
Effects
of hormone replacement therapy on fibrinolysis in postmenopausal
women.
N Engl J
Med.
1997;
336
683-690
MissingFormLabel
- 22
Kommission Hormontoxikologie der Deutschen
Gesellschaft für
Endokrinologie .
Östrogen/Gestagen-Substitution
während und nach den
Wechseljahren.
Endokrinologie.
1996;
20
122-125
MissingFormLabel
- 23
Mant J, Painter R, Vessey M.
Risk
of myocardial infarction, angina and stroke in users of oral contraceptives:
updated analysis of a cohort study.
Br J Obstet
Gynaekcol.
1998;
105
890-896
MissingFormLabel
- 24
Mendelsohn M E, Karas R H.
Mechanism
of Disease: The protective effects of Estrogen on the cardiovascular
system.
N Engl J
Med.
1999;
340
1801
MissingFormLabel
- 25
O`Brian J E, Peterson E D, Keeler G P.
Relation
between estrogen replacement therapy and restenosis after percutaneous coronary
interventions.
J Am Coll
Cardiol.
1996;
28
1111-1118
MissingFormLabel
- 26
Oger E, Scarabin P Y.
Assessment
of the risk for venous thromboembolism among users of the hormone replacement
therapy.
Drugs
Aging.
1999;
14
55-61
MissingFormLabel
- 27
Peterson L.
Estrogen
replacement therapy and coronary heart disease.
Curr Opin
Cardiol.
1998;
13
223-231
MissingFormLabel
- 28
Psaty B M, Heckbert S R, Atkins D.
et al .
The risk of myocardial infarction associated with the
combined use of estrogen and progestin in postmenopausal women.
Arch
Int
Med.
1994;
154
1333-1339
MissingFormLabel
- 29
Rich-Edwards J W, Manson J, Hennekens C H, Buring J E.
The
primary prevention of coronary heart disease in women.
N Engl J
Med.
1995;
332
1758-1766
MissingFormLabel
- 30
Rich-Edwards J W, Hennekens C H.
Postmenopuasal
hormones and coronary heart disease.
Curr Opin
Cardiol.
1996;
12
440-446
MissingFormLabel
- 31
Ringe J D, Nickelsen T h.
Raloxifen.
Arzneimitteltherapie.
1999;
17
113-120
MissingFormLabel
- 32
Schunkert H, Danser A H-J, Hense H, Derks F H-M, Kürzinger S, Rigger G A-J.
Effects
of estrogen replacement therapy of the renin-angiotensin system in
postmenopausal
women.
Circulation.
1997;
95
39-45
MissingFormLabel
- 33
Sherif K.
Benefits
and risks of oral contraceptives.
Am J Obstet
Gynecol.
1999;
180
343-348
MissingFormLabel
- 34
Skouby S O.
Oral
contraceptives and venous thrombosis: End of the debate?.
Eur J
Contracept Reprod Health
Care.
1998;
3
59-64
MissingFormLabel
- 35
Stadel B V.
Oral
contraceptives and cardiovascular disease.
N Engl J
Med.
1993;
328
1069-1075
MissingFormLabel
- 36
Stampfer M J, Willett W C, Colditz G A, Rosner B, Speizer F E, Hennekens C H.
A
prospective study of the meonopausal estrogen therapy and coronary heart
disease.
N Engl J
Med.
1985;
313
1044-1049
MissingFormLabel
- 37
Stampfer M J, Colditz G A, Willett W C. et
al .
Postmenopausal estrogen therapy and cardiovascular
disease.
N Engl J
Med.
1991;
325
756-762
MissingFormLabel
- 38
Stampfer M J, Colditz G A.
Estrogen
replacement therapy and coronary heart disase: A quantitative assessment of the
epidemiologic evidence.
Prev
Med.
1991;
20
47-63
MissingFormLabel
- 39
Sullivan J M, El-Zeky F, Vander
Zwang R, Ramanathan K B.
Effect
on survival of estrogen replacement therapy after coronary artery bypass
grafting.
Am J
Cardiol.
1997;
79
847-850
MissingFormLabel
- 40
Sourander L, Rajala T, Makinen I. et
al .
Cardiovascular and cancer morbidity and mortality and sudden
cardiac death in postmenopausal women on estrogen replacement
therapy.
Lancet.
1998;
352
1965-1969
MissingFormLabel
- 41
Todd J, Lawrenson R, Farmer R D, Williams T J, Leyden G M.
Venous
thromboembolic disease and combined oral contraceptives: A reanalysis of the
MedPlus database.
Hum
Reprod.
1999;
14
1500-1005
MissingFormLabel
- 42
Weiss G.
Risk of
venous thromboembolism with third generation oral contraceptives. A
review.
Am J Obstet
Gynecol.
1999;
180
295-301
MissingFormLabel
- 43
The writing group for the PEPI
trial .
Effects of estrogen or Estrogen/Progestin Regimens on
heart disease: Risk factors in postmenopausal women. The postmenopausal
Estrogen/Progestin interventions(PEPI) trial.
J Am Med
Ass.
1995;
273
199-208
MissingFormLabel
- 44
Windler E.
Prävention
kardiovaskulärer Erkrankungen durch Hormonsubstitution in der
Postmenopause.
Zentralbl
Gynäkol.
1996;
118
188-197
MissingFormLabel
Korrespondenz
Privatdozent Dr. W. Lengfelder
Klinik für
Kardiologie und Internistische Intensivmedizin Klinikum
Minden
Postfach
32390 Minden
Telefon: 0571/8013012,
Fax: 0571/8013015